{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:00:04Z","timestamp":1783630804145,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2018YFC1312101"],"award-info":[{"award-number":["2018YFC1312101"]}]},{"name":"Chinese Academy of Medical Science Initiative for Innovative Medicine","award":["CAMS-2016-I2M-1-010"],"award-info":[{"award-number":["CAMS-2016-I2M-1-010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11523-021-00823-4","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T10:03:49Z","timestamp":1625133829000},"page":"591-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct02833155","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jiani","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"823_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-3-319-70197-4_9","volume":"173","author":"LE Flaum","year":"2018","unstructured":"Flaum LE, Gradishar WJ. Advances in endocrine therapy for postmenopausal metastatic breast cancer. Cancer Treat Res. 2018;173:141\u201354. https:\/\/doi.org\/10.1007\/978-3-319-70197-4_9.","journal-title":"Cancer Treat Res"},{"key":"823_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/bs.pmbts.2016.09.009","volume":"144","author":"S Radhi","year":"2016","unstructured":"Radhi S. Molecular changes during breast cancer and mechanisms of endocrine therapy resistance. Prog Mol Biol Transl Sci. 2016;144:539\u201362. https:\/\/doi.org\/10.1016\/bs.pmbts.2016.09.009.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"9","key":"823_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrclinonc.2015.99","volume":"12","author":"CD Hart","year":"2015","unstructured":"Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015;12(9):541\u201352. https:\/\/doi.org\/10.1038\/nrclinonc.2015.99.","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"823_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"issue":"18","key":"823_CR5","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Palunch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"issue":"9","key":"823_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"issue":"1","key":"823_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21873\/anticanres.11286","volume":"37","author":"C Damaskos","year":"2017","unstructured":"Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T, et al. Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res. 2017;37(1):35\u201346. https:\/\/doi.org\/10.21873\/anticanres.11286.","journal-title":"Anticancer Res"},{"key":"823_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcancer.2018.01.007","volume":"51","author":"B Pasculli","year":"2018","unstructured":"Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin Cancer Biol. 2018;51:22\u201335. https:\/\/doi.org\/10.1016\/j.semcancer.2018.01.007.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"823_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12885-019-5403-0","volume":"19","author":"BP de Almeida","year":"2019","unstructured":"de Almeida BP, Apolonio JD, Binnie A, Castelo-Branco P. Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers. BMC Cancer. 2019;19(1):219. https:\/\/doi.org\/10.1186\/s12885-019-5403-0.","journal-title":"BMC Cancer"},{"issue":"7645","key":"823_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature21409","volume":"543","author":"JL Guerriero","year":"2017","unstructured":"Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017;543(7645):428\u201332. https:\/\/doi.org\/10.1038\/nature21409.","journal-title":"Nature"},{"issue":"6","key":"823_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1124\/dmd.119.089953","volume":"48","author":"D You","year":"2020","unstructured":"You D, Richardson JR, Aleksunes LM. Epigenetic regulation of multidrug resistance protein 1 and breast cancer resistance protein transporters by histone deacetylase inhibition. Drug Metab Dispos. 2020;48(6):459\u201380. https:\/\/doi.org\/10.1124\/dmd.119.089953.","journal-title":"Drug Metab Dispos"},{"key":"823_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18:7. https:\/\/doi.org\/10.3390\/ijms18071414.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"823_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2017.05.008","volume":"32","author":"K Qu","year":"2017","unstructured":"Qu K, Zaba LC, Satpathy AT, Giresi PG, Li R, Jin Y, et al. Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell. 2017;32(1):27\u201341. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.008.","journal-title":"Cancer Cell"},{"key":"823_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","volume":"138","author":"JJ McClure","year":"2018","unstructured":"McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183\u2013211. https:\/\/doi.org\/10.1016\/bs.acr.2018.02.006.","journal-title":"Adv Cancer Res"},{"issue":"17","key":"823_CR15","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1200\/jco.2012.43.7251","volume":"31","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128\u201335. https:\/\/doi.org\/10.1200\/jco.2012.43.7251.","journal-title":"J Clin Oncol"},{"issue":"17","key":"823_CR16","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/jco.2005.02.188","volume":"23","author":"QC Ryan","year":"2005","unstructured":"Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23(17):3912\u201322. https:\/\/doi.org\/10.1200\/jco.2005.02.188.","journal-title":"J Clin Oncol"},{"issue":"6","key":"823_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(6):806\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(19)30164-0.","journal-title":"Lancet Oncol"},{"key":"823_CR18","unstructured":"Derendorf H, Schmidt S. Rowland and Tozer\u2019s clinical pharmacokinetics and pharmacodynamics: concepts and applications. Chapter, vol 11. 2020. p. 176\u2013179."},{"key":"823_CR19","first-page":"P280","volume":"18","author":"KX Liu","year":"2020","unstructured":"Liu KX. Clinical pharmacokinetics evaluation of new drugs. Clin Pharmacokinet. 2020;18:P280-282.","journal-title":"Clin Pharmacokinet"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-021-00823-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T11:10:15Z","timestamp":1633000215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-021-00823-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1007\/s11523-021-00823-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"7 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the National Key Research and Development Program of China (No. 2018YFC1312101) and Chinese Academy of Medical Science Initiative for Innovative Medicine (No. CAMS-2016-I2M-1-010).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jiani Wang, Qingyuan Zhang, Qiao Li, Yuxin Mu, Jing Jing, Huiping Li, Wei Li, Jingfen Wang, Guohua Yu, Xian Wang, Quchang Ouyang, Jing Hao, Liang Lu, Li Zhou, Jin Guan, Qing Li, and Binghe Xu declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This clinical trial received EC approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This clinical trial obtained informed consent from all participated subjects.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and analyzed during the current study are not publicly available due the confidential requirements of the new product, but are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conception and design: Q. Li and B. Xu. Development of methodology: Q. Li, J. Wang, Q. Li, B. Xu. Acquisition of data (acquired and managed patients, provided facilities, etc.): J. Wang, Q. Zhang, Q. Li, Y. Mu, J. Jing, H. Li, W. Li, J. Wang, G. Yu, X. Wang, Q. Ouyang, Q. Li, and B. Xu. Analysis and interpretation of data (e.g., statistical analysis, computational analysis): L. Lu, L. Zhou, J. Guan, J. Hao, and J. Wang. Writing, review, and\/or revision of the manuscript: J. Wang, Q. Li, and B. Xu. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Wang, Q. Zhang, Q. Li, and Y. Mu. Study supervision: Q. Li and B. Xu.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}